Syncor to distribute PerImmune MoAb

Article

Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a

Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a human monoclonal antibody for the diagnosis and staging of colorectal cancer that PerImmune is developing. Syncor also announced that it has completed its acquisition of the iodine-123 business of Golden Pharmaceuticals of Golden, CO (SCAN 2/19/97).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.